Sign Up Today and Learn More About Accent Therapeutics Stock
Invest in or calculate the value of your shares in Accent Therapeutics or other pre-IPO companies through EquityZen's platform.
Accent Therapeutics Stock (ACTH)
Accent Therapeutics is a biopharmaceutical company.
About Accent Therapeutics Stock
Founded
2017
Headquarters
Lexington, MA, US
Industries
Science and Engineering, Health Care, Biotechnology
Accent Therapeutics Press Mentions
Stay in the know about the latest news on Accent Therapeutics
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Novel KIF18A Inhibitor ATX-295 and Receives FDA Fast Track Designation for Lead Assets ATX-295 and DHX9 Inhibitor ATX-559
prnewswire • Apr 15, 2025
DHX9 RNA helicase inhibitors and their uses
patents • Apr 02, 2025
Inhibitors of rna helicase dhx9 and uses thereof
patents • Apr 02, 2025
Inhibitors of RNA helicase DHX9 and uses thereof
patents • Apr 02, 2025
Accent Therapeutics to Present Data on Lead Programs ATX-559 and ATX-295 at the 2025 American Association for Cancer Research Annual Meeting
prnewswire • Mar 25, 2025
Accent Therapeutics Management
Leadership team at Accent Therapeutics
President, CSO & Co-Founder
Robert A. Copeland
CFO
Nicole Heifner
Join now and verify your accreditation status to gain access to:
- Accent Therapeutics Current Valuation
- Accent Therapeutics Stock Price
- Accent Therapeutics Management
- Available deals in Accent Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Accent Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Accent Therapeutics Revenue and Financials
- Accent Therapeutics Highlights
- Accent Therapeutics Business Model
- Accent Therapeutics Risk Factors
- Accent Therapeutics Research Report from SACRA Research
Trading Accent Therapeutics Stock
How to invest in Accent Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Accent Therapeutics through EquityZen funds. These investments are made available by existing Accent Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Accent Therapeutics stock?
Shareholders can sell their Accent Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
